Arrowhead Pharmaceuticals, Inc.
ARWR
$79.04
$1.301.67%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 73.74M | 264.03M | 256.47M | 27.77M | 542.71M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 73.74M | 264.03M | 256.47M | 27.77M | 542.71M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 73.74M | 264.03M | 256.47M | 27.77M | 542.71M |
| SG&A Expenses | 49.34M | 49.70M | 31.29M | 37.41M | 35.14M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 215.00M | 223.22M | 212.37M | 193.32M | 161.51M |
| Operating Income | -141.26M | 40.81M | 44.11M | -165.55M | 381.20M |
| Income Before Tax | -137.57M | 28.27M | 36.12M | -179.09M | 369.62M |
| Income Tax Expenses | 7.00K | 29.00K | 20.00M | -437.00K | 1.75M |
| Earnings from Continuing Operations | -137.57M | 28.24M | 16.12M | -178.65M | 367.86M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 4.84M | 2.57M | -39.87M | 3.41M | 2.58M |
| Net Income | -132.73M | 30.81M | -23.75M | -175.24M | 370.45M |
| EBIT | -141.26M | 40.81M | 44.11M | -165.55M | 381.20M |
| EBITDA | -134.89M | 47.20M | 50.49M | -159.33M | 387.29M |
| EPS Basic | -0.93 | 0.22 | -0.17 | -1.26 | 2.78 |
| Normalized Basic EPS | -0.65 | 0.15 | -0.13 | -0.78 | 1.75 |
| EPS Diluted | -0.93 | 0.22 | -0.17 | -1.26 | 2.75 |
| Normalized Diluted EPS | -0.65 | 0.14 | -0.13 | -0.78 | 1.74 |
| Average Basic Shares Outstanding | 142.42M | 137.04M | 137.88M | 139.04M | 133.36M |
| Average Diluted Shares Outstanding | 142.42M | 140.71M | 137.88M | 139.04M | 134.48M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |